Navigation Links
YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Date:9/4/2007

zumab at three dose levels (100mg, 200mg and 400mg weekly) with palliative radiation (30 Gy in 10 fractions). The data will be used to select the optimal effective dose for the randomized Phase II component of the study, in which Overall Survival will be the primary endpoint.

Of the six patients enrolled in the 1st cohort (100mg), four Partial Response (PR) and two Stable Disease (SD) were reported as at August 14, 2007. Median Overall Survival of the group was 41.5 weeks. All patients ultimately progressed. Two severe adverse events have been reported, neither causally attributable to nimotuzumab. A notable absence of grade III/IV rash or diarrhea in this cohort was reported.

Of the seven patients enrolled in the 2nd cohort (200mg) of the study, two PR and five SD were reported as at August 14, 2007 Median overall survival of the group has not been reached but currently exceeds 25 weeks. There has been a notable absence of grade III/IV rash or diarrhea reported in this cohort.

Enrolment is now ongoing into the third cohort, to be treated at 400 mg per dose level, and accrual is anticipated to be completed by the end of 2007.

YM is conducting the trial in Canada and Kuhnil Pharmaceutical Co. is conducting a parallel trial in Korea with a common protocol. This structure is designed to accelerate overall recruitment and lower the costs to the participants. The interim report from Phase I Korean patients is anticipated early in 2008.

The poster presentation is entitled "Preliminary Results Of An Escalating Dose (Phase I /II Clinical) Trial Of The Anti EGFR Monoclonal Antibody Nimotuzumab In Combination With External Radiotherapy In Patients Diagnosed With Stage IIB, III or IV NSCLC Unsuitable For Radical Therapy" by Gwyn Bebb, Colum Smith, Anthony Brade, Stewart Rorke and Igor Sherman. The poster, P3 - 023, will be on display on September 5 & 6 at Atlantic Halls 5 - 8 in poster session 3 - Novel Therapeutics: Molecular Therapeutics.


'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Veracyte, Inc. (Nasdaq: ... the field of molecular cytology, today announced the promotion ... Mr. Hall joined Veracyte in 2010 as chief ... endocrinology. Since 2012, he has led sales, marketing, laboratory ... and billing functions. As chief operating officer, Mr. Hall ...
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... -- This report analyzes the worldwide markets for Bioinformatics in ... Biocontent. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:9/16/2014)... University scientists who created a deicing film for radar ... a transparent coating for glass. , The new ... could keep glass surfaces from windshields to skyscrapers free ... radio frequencies (RF). , The technology was introduced ... Applied Materials and Interfaces . , The material ...
Breaking Biology Technology:Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2
... The Netherlands, September 26 A consortium of,experts in ... have,joined forces to develop a novel pandemic influenza vaccine ... awarded a grant of,EUR3.5 million from the European Union ... new vaccine. The so-called FluVac project will be,coordinated by ...
... Glycominds Ltd., a biodiagnostics,company specializing in glycan biomarkers ... cancer, announced today that has,entered the Biomolecular Photonic ... the Government of Israel to improve in-vivo imaging ... BMP consortium was,approved for three years and was ...
... NanoBio(R) Corporation, a,biopharmaceutical company developing novel anti-infective topicals ... today announced,the addition of four new scientists to ... Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, Ph.D.,and ... and commercializing,its novel topical anti-infectives and mucosal vaccines. ...
Cached Biology Technology:European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine 2European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine 3Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 3
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
(Date:9/17/2014)... decline, grasses have returned to some once-denuded patches of ... those places seems healthy again, but a new study ... coastal protection remains diminished. , "We,ve got ... back," said ecologist Mark Bertness, professor of biology at ... journal Biological Conservation . "The metric of a ...
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Being social: Learning from the behavior of birds 2
... life on earth, yet freshwater animals and plants are ... The dominant causes are the many stressors that affect ... by alien species, dams, over-abstraction, many forms of pollution ... sensitive to climate change which now exacerbates all these ...
... in the September 2008 issue of BioScience ... and Its Use in Basic and Applied Insect Science. ... genomes and comparative genomics are providing new insights into ... to a variety of biotechnological applications to pest management, ...
... have been diagnosed with Parkinson,s disease, could benefit from ... Craig from Queen,s School of Psychology is researching the ... have difficulty controlling their movements. The work is ... European Research Council. Dr Craig is the only ...
Cached Biology News:Water: stressed-out and overheated 2BioScience tip sheet, September 2008 2New sensory devices will aid Parkinson's and stroke patients 2
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
... is the first all-inclusive collection of key ... Expression System. Methods developed by the leaders ... step-by-step protocols. This book will guide you ... strain construction and analysis, to production of ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
Biology Products: